Table 2.

Characteristics of relapsed acute promyelocytic leukemia patients

Patient no.	Risk category	Age (y)	Sex	Cytogenetics	FLT3 status	Time to first relapse (mo)	Type of first relapse
1	High	52	F	Diploid	ND	9.2	Molecular*
2	Low	42	M	46XY t(15;17) [20]	ND	79.5	Hematological/molecular
3	High	38	M	46XY t(15;17) [19]	ND	9	Hematological/molecular
4	High	79	M	46XY t(15;17), der (17) i (17) (q10) [18]; 46 XY [2]	Neg	12.4	Molecular*
5	High	18	M	46XY t(15;17) [19]	ND	9.4	Molecular*
6	Low	19	F	Diploid	Neg	9.5	Hematological
7	High	35	M	46XY t(15;17) [16]; 46 idem, del 7 [1]; 46 XY [3]	Neg	7.9	Hematological

BM, bone marrow; CNS, central nervous system; F, female; M, Male; MRD-SCT, matched-related donor stem cell transplantation; mo, months; No., number; ND, not done; Neg, negative.

^*Molecular relapses: Patient No.1 experienced a molecular relapse after 9.2 mo received salvage ATRA/ATO/GO achieved molecular remission, but then had a hematological relapse (BM+CNS) with time to hematological relapse of 18.8 mo (9.6 mo after molecular relapse). Patient No. 4 experienced a molecular relapse after 12.4 mo received salvage GO without achieving molecular remission and had a hematological relapse (CNS alone) with time to hematological relapse of 16.4 mo (4 mo after molecular relapse). Patient No. 5 experienced a molecular relapse after 9.4 mo received salvage ATRA/ATO/GO/IDA achieved molecular remission which was followed by MRD-SCT.